Effect of olanzapine in delirium of poisoning patient
Phase 3
- Conditions
- delirium patient admitted in ICU.
- Registration Number
- IRCT20190928044909N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Inclusion criteria included patients over 18 years of age who had acute intoxication without dementia
Exclusion Criteria
Patients who take antipsychotic drugs for any reason
Patients are using alcohol or benzodiazepine
Patients who were allergic to haloperidol or olanzapine,
Patients who have severe agitation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the symptoms of delirium: All symptoms related to decreased attention and memory impairment are eliminated. Response to treatment is based on changes in MDAS scores.impairment are resolved. The response to treatment is based on improvement in the MDAS score. Timepoint: Treatment results are evaluated by the researcher on days 3 and 5. Method of measurement: Delirio intensity is measured on the MDAS score, which includes 10 items and 4 points.This intensity will be rated in MDAS <= 15 as mild, in 16 <= MDAS <= 22 as moderate and in 23 <= MDAS <= 30, it will be rated severe. The remission index for this disease based on this score is MDAS values less than 10.
- Secondary Outcome Measures
Name Time Method